Italian company Recordati acquires Sanofi's Enjaymo for $825M, with potential for $250M more, for CAD treatment, closing by end 2024.
Italian pharmaceutical company Recordati has acquired the global rights to Sanofi's Enjaymo, the only FDA-approved treatment for cold agglutinin disease (CAD), for $825 million, with up to $250 million in potential milestone payments. The deal is expected to close by the end of 2024, pending regulatory approval. Recordati plans to fund the acquisition with existing cash and new bank debt, while maintaining its dividend and capital allocation policies.
October 04, 2024
17 Articles